This technology includes novel compounds which can be expected to selectively target the 5HT6 receptor, which is implicated in CNS-related diseases. In particular 5HT6 antagonism has been implicated in cognitive impairment, AD/PD and drug abuse/alcohol abuse related disorders. 5HT6 compounds have also shown to reduce appetite and induce weight loss. As such, compounds that can selectively antagonize 5HT6 along with an additional signaling pathway implicated in such diseases like inducible nitric oxide synthase (iNOS) may be valuable for such CNS mediated diseases. Here in we have designed and synthesized compounds which can have unique 5HT6 antagonism as well as iNOS inhibition to offer additive benefits or synergism in alleviating memory and cognitive deficits, reduce obesity and food/drug intake.